SCHEMBL28679435

SCHEMBL28679435

O=C(Nc1ncc(-c2ccccc2Cl)[nH]1)c1cc(-c2ccccc2)nc2ccc(OC(F)(F)F)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 2/20 0.47
▸ PLA2G2A P14555 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.42
▸ CA9 Q16790 3/20 0.42
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CYP3A4 P08684 2/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ TACR3 P29371 1/20 0.41
▸ RUVBL1 Q9Y265 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ CSNK2B P67870 1/20 0.41
▸ PIM3 Q86V86 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28691056 0.86 PLA2G2A (0.53) DHODHPLA2G2ACA9CA12CA1
SCHEMBL28672796 0.85 MCL1 (0.46) PLA2G2A
SCHEMBL1900644 0.79 STAT3 (0.57) DHODHPLA2G2AKDM4ENPSR1RUVBL1
SCHEMBL28679437 0.77 DHODH (0.48) DHODHPLA2G2ATRPV1CA9CA12
SCHEMBL1896811 0.74 DHODH (0.72) DHODHPLA2G2ATRPV1KDM4ECYP2C9
SCHEMBL28696167 0.73 MCL1 (0.55) PLA2G2ACA9CA12CA1CA2
SCHEMBL28931959 0.73 STAT3 (0.59) CYP3A4KDM4ETACR3USP2ALDH1A1
SCHEMBL28691066 0.73 CYP3A4 (0.68) CYP3A4KDM4ENPSR1TACR3RUVBL1
SCHEMBL1900802 0.72 STAT3 (0.70) DHODHPLA2G2ATRPV1CA9CA12
SCHEMBL6309512 0.72 DHODH (0.73) DHODHPLA2G2AKDM4ECYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113747920-A Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-12-03 — — CN disclosed
CN-112703001-A Combination cancer therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-04-23 — — CN disclosed
Send feedback